101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020
HB5340

 

Introduced , by Rep. Anna Moeller

 

SYNOPSIS AS INTRODUCED:
 
New Act

    Creates the Illinois Pharmaceutical Collaborative Act. Requires the Department of Healthcare and Family Services to convene the Illinois Pharmaceutical Collaborative (Collaborative) to address the rising cost of pharmaceutical drugs. Provides that the Collaborative shall be chaired by the Director of Healthcare and Family Services and its activities shall be coordinated by the Department. Provides that the Collaborative shall meet twice a year and that its mission shall be to coordinate the efforts of State and local government entities to identify and implement opportunities for cost savings with regard to the purchase of pharmaceuticals, particularly pharmaceuticals that are considered high-cost drugs. Contains provisions concerning the composition and duties of the Collaborative; Department contracts with manufacturers and suppliers of single source or multisource pharmaceuticals; the appointment of a pharmaceutical benefits manager; State participation in a prescription drug bulk purchasing program; and reporting requirements.


LRB101 19204 KTG 68667 b

FISCAL NOTE ACT MAY APPLY

 

 

A BILL FOR

 

HB5340LRB101 19204 KTG 68667 b

1    AN ACT concerning pharmaceuticals.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 1. Short title. This Act may be cited as the
5Illinois Pharmaceutical Collaborative Act.
 
6    Section 5. Findings and declarations.
7    (a) Despite prior legislative attempts to encourage the
8participation of State and local entities in a bulk purchasing
9program aimed at lowering government expenses, pharmaceutical
10drug prices are skyrocketing, and State and local spending on
11these drugs is increasing.
12    (b) This Act is intended to improve the situation by
13revising the organizational framework to better facilitate the
14cooperation of State and local agencies to reduce the costs of
15pharmaceuticals they purchase.
16    (c) Both State and local entities will benefit from a
17collaboration to track high-cost pharmaceuticals, achieve the
18best value in procurement and pricing of pharmaceuticals,
19identify important issues related to prescription drug pricing
20and procurement, and increase the Department of Healthcare and
21Family Services purchasing power.
 
22    Section 10. The Illinois Pharmaceutical Collaborative.

 

 

HB5340- 2 -LRB101 19204 KTG 68667 b

1    (a) The Department of Healthcare and Family Services shall
2convene the Illinois Pharmaceutical Collaborative in
3accordance with this Act to address the rising cost of
4pharmaceutical drugs.
5    (b) The Illinois Pharmaceutical Collaborative shall be
6chaired by the Director of Healthcare and Family Services, or
7his or her designee.
8    (c) The activities of the Illinois Pharmaceutical
9Collaborative shall be coordinated by the Department of
10Healthcare and Family Services.
11    (d) The Illinois Pharmaceutical Collaborative shall meet
12at least twice per year. The mission of the Illinois
13Pharmaceutical Collaborative shall be to coordinate the
14efforts of State and local government entities to identify and
15implement opportunities for cost savings with regard to the
16purchase of pharmaceuticals, particularly pharmaceuticals that
17are considered high-cost drugs.
 
18    Section 15. Composition of the Illinois Pharmaceutical
19Collaborative.
20    (a) The following agencies shall be members of, and shall
21each appoint a representative to, the Illinois Pharmaceutical
22Collaborative:
23        (1) The Department of Corrections.
24        (2) The Department of Veterans' Affairs.
25        (3) The Department of Human Services.

 

 

HB5340- 3 -LRB101 19204 KTG 68667 b

1        (4) The Department of Financial and Professional
2    Regulation.
3        (5) The Department of Central Management Services.
4        (6) The Department of Labor.
5        (7) The Department of Public Health.
6        (8) The Board of Higher Education.
7    (b) The Speaker of the House of Representatives and the
8President of the Senate shall each appoint a representative to
9the Illinois Pharmaceutical Collaborative. The Minority Leader
10of the House of Representatives and the Minority Leader of the
11Senate shall each appoint a representative to the Illinois
12Pharmaceutical Collaborative.
13    (c) Other State or local government agencies may also
14appoint a representative to the Illinois Pharmaceutical
15Collaborative, as determined by the Governor.
 
16    Section 20. Duties.
17    (a) The Illinois Pharmaceutical Collaborative shall
18perform all of the following functions:
19        (1) Coordinate best value clinical treatment protocols
20    among members of the Illinois Pharmaceutical
21    Collaborative.
22        (2) Leverage State and local governmental efficiencies
23    and methodologies to achieve best value procurement,
24    purchasing, and negotiation with manufacturers for
25    discounts on pharmaceuticals.

 

 

HB5340- 4 -LRB101 19204 KTG 68667 b

1        (3) Investigate and implement options and strategies
2    to achieve the greatest savings on pharmaceuticals,
3    including all of the following:
4            (A) Encourage members of the Illinois
5        Pharmaceutical Collaborative to develop and adopt the
6        State's preferred drug list overseen by the Department
7        of Healthcare and Family Services.
8            (B) Obtain the maximum transparency possible in
9        administering the State's preferred drug list,
10        including all forms of rebates, mail order income, and
11        spreads.
12            (C) Join other State pharmaceutical purchasing
13        programs in a consortium that is open to other private
14        and public purchasers of pharmaceuticals.
15            (D) Join an independent association that produces
16        comparative effectiveness research on pharmaceuticals
17        using systematic reviews of scientific or medical
18        studies that use clinical trials and are subject to
19        peer review. The association's investigators shall
20        comply with a conflict-of-interest policy that
21        includes a formal, annual, written, self-declaration
22        of no financial interest in any pharmaceutical company
23        for at least the duration of the time that the person
24        is working for the association.
25            (E) Obtain access to the drug discount program
26        established under Section 340B of the federal Public

 

 

HB5340- 5 -LRB101 19204 KTG 68667 b

1        Health Service Act (42 U.S.C. 256b).
2        (4) Establish and monitor performance and quality
3    standards for protocols, guidelines, and contracts created
4    for members of the Illinois Pharmaceutical Collaborative.
5        (5) Work with members of the Illinois Pharmaceutical
6    Collaborative to track access to and State expenditures on
7    specified high-cost drugs to inform the budget process.
8        (6) Recommend high-cost pharmaceuticals for cost value
9    review by independent research organizations.
10        (7) Track new pharmaceuticals that are under review by
11    the federal Food and Drug Administration, drugs that are
12    likely to come on to the market in the near future, and
13    drugs that may become high cost.
14        (8) Act as a forum for discussion where issues of
15    interest related to pharmaceuticals can be identified and
16    addressed.
17        (9) Collect information on drugs approved by the
18    federal Food and Drug Administration that will be sold and
19    used by members of the Illinois Pharmaceutical
20    Collaborative.
21    (b) Nothing in this Section shall be construed to require
22the sharing of information that is prohibited by any other
23provision of law or contractual agreement, or the disclosure of
24information that may adversely affect potential pharmaceutical
25procurement by any State agency.
 

 

 

HB5340- 6 -LRB101 19204 KTG 68667 b

1    Section 25. Workgroups. The Illinois Pharmaceutical
2Collaborative shall form several workgroups in service of its
3goals that shall meet at least quarterly. The co-chairpersons
4of the Illinois Pharmaceutical Collaborative shall meet with
5the workgroup leads monthly. The workgroups formed shall
6include all of the following:
7        (1) A clinical workgroup.
8        (2) A policy workgroup.
9        (3) A procurement workgroup.
10        (4) A local outreach workgroup.
 
11    Section 30. Contracts.
12    (a) Notwithstanding any other provision of law, the
13Department of Healthcare and Family Services, in accordance
14with this Act, may enter into exclusive or nonexclusive
15contracts on a bid or negotiated basis with manufacturers and
16suppliers of single source or multisource pharmaceuticals. The
17Department of Healthcare and Family Services may obtain from
18those manufacturers and suppliers discounts, rebates, or
19refunds based on quantities purchased insofar as permissible
20under federal law. Contracts entered into in accordance this
21Act may include price discounts, rebates, refunds, or other
22strategies aimed at managing escalating prescription
23pharmaceutical drug prices.
24    (b) Contracts under this Act shall be exempt from the
25Illinois Procurement Code.
 

 

 

HB5340- 7 -LRB101 19204 KTG 68667 b

1    Section 35. Pharmaceutical benefits manager. The
2Department of Healthcare and Family Services may appoint and
3contract with a pharmaceutical benefits manager or other entity
4to facilitate the acquisition of pharmaceuticals purchased in
5accordance with this Act. The pharmaceutical benefits manager
6or other entity may do all of the following:
7        (1) Negotiate price discounts, rebates, or other
8    options that achieve the greatest savings on
9    pharmaceuticals with pharmaceutical manufacturers and
10    wholesalers.
11        (2) Purchase pharmaceuticals for participating State
12    or local governmental entities.
13        (3) Act as a consultant to the Department of Healthcare
14    and Family Services and the Illinois Pharmaceutical
15    Collaborative.
 
16    Section 40. Prescription drug bulk purchasing program.
17    (a) The following State agencies shall participate in the
18prescription drug bulk purchasing program authorized under
19this Act.
20        (1) The Department of Public Health.
21        (2) The Department of Corrections.
22        (3) The Department of Human Services' Division of
23    Developmental Disabilities.
24    (b) Any State, local, or public agency governmental entity,

 

 

HB5340- 8 -LRB101 19204 KTG 68667 b

1other than a State agency specified in subsection (a), may
2elect to participate in the coordinated purchasing program.
 
3    Section 45. Reports. On or before July 1, 2021, the
4Department of Healthcare and Family Services shall submit a
5report to the appropriate policy and fiscal committees of the
6General Assembly on the activities of the Illinois
7Pharmaceutical Collaborative. The report shall be filed
8annually until 2025. The report shall include, but not be
9limited to, all of the following:
10        (1) The number and a description of the contracts
11    entered into with pharmaceutical benefits managers or
12    other pharmaceutical drug purchasing agents.
13        (2) The number and a description of entities that elect
14    to participate in pharmaceutical purchasing coordinated by
15    the Illinois Pharmaceutical Collaborative.
16        (3) The per month cost of pharmaceuticals for each
17    member agency.
18        (4) Other options and strategies that have been or will
19    be undertaken by the Illinois Pharmaceutical Collaborative
20    in accordance with this Act.
21        (5) The progress made with regard to the investigation
22    and implementation of options and strategies to achieve the
23    greatest savings on pharmaceuticals.
24        (6) The estimated cost savings attributable to
25    activities that have been or will be undertaken by the

 

 

HB5340- 9 -LRB101 19204 KTG 68667 b

1    Illinois Pharmaceutical Collaborative.